Impact of a Warning CPOE System on the Inappropriate Pill Splitting of Prescribed Medications in Outpatients

Chia-Chen Hsu1, Chia-Yu Chou2,3,4,5, Chia-Lin Chou1, Chin-Chin Ho1,6, Tzeng-Ji Chen7,8, Shu-Chiung Chiang7, Min-Shan Wu1, Sen-Wen Wang1, Chung-Yuan Lee9, Yueh-Ching Chou1,3,6*

1. Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, 2. Department of Critical Care Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 3. Department and Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, 4. Department of Internal Medicine, School of Medicine, National Defense Medical Center, Taipei, Taiwan, 5. Department of Medicine, Tzu Chi University, Hualien, Taiwan, 6. College of Pharmacy, Taipei Medical University, Taipei, Taiwan, 7. Institute of Hospital and Health Care Administration, School of Medicine, National Yang-Ming University, Taipei, Taiwan, 8. Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 9. Information Management Office, Taipei Veterans General Hospital, Taipei, Taiwan

*ycchou@vghtpe.gov.tw

Abstract

**Background:** Prescribing inappropriate pill splitting is not rare in clinical practice. To reduce inappropriate pill splitting, we developed an automatic warning system linked to a computerized physician order entry (CPOE) system for special oral formulation drugs in outpatient settings. We examined the impact of the warning system on inappropriate prescribing of pill splitting and assess prescribers’ responses to the warnings.

**Methods:** Drugs with extended-release or enteric-coated formulations that were not originally intended to be split were recognized as “special oral formulations”. A hard-stop system which could examine non-integer doses of drugs with special oral formulations, provide warnings to interrupt inappropriate prescriptions was integrated in CPOE in a medical center since June 2010. We designed an intervention study to compare the inappropriate splitting before and after the implementation of the warning system (baseline period 2010 January to May vs. intervention period 2010 June to 2011 August). During the intervention period, prescription changes in response to a warning were logged and analyzed.

**Results:** A total of 470,611 prescribed drug items with 34 different drugs with special oral formulations were prescribed in the study period. During the 15-month intervention period, 909 warnings for 26 different drugs were triggered among 354,523 prescribed drug items with special oral formulations. The warning rate of inappropriate splitting in the late intervention period was lower than those in
baseline period (0.16% vs. 0.61%, incidence rate ratio 0.27, 95% CI 0.23–0.31, \( P<0.001 \)). In respond to warnings, physicians had to make adjustments, of which the majority was changing to an unsplit pill (72.9%).

**Conclusions:** The interruptive warning system could avoid the prescriptions with inappropriate pill splitting. Accordingly, physicians changed their behavior of prescribing special oral formulations regarding inappropriate pill splitting. We suggest the establishment of such system to target special oral formulations with warnings to prevent inappropriate pill splitting.

---

**Introduction**

Special oral formulations, such as extended-release (ER) or enteric-coated (EC) formulations, are an important technology for achieving specific pharmacokinetic profiles [1]. Special oral formulations are usually unsuitable for splitting. Splitting of ER tablets may cause dose dumping and lead to dose-dependent side effects. One adverse drug event (ADE) case was reported in which a crushed extended-release nifedipine tablet resulted in a fatal outcome [2]. As noted in our previously published study, 1% of drugs with special oral formulations (ER or EC tablets not allowed to split) were inappropriately prescribed as split pills at ambulatory settings [3]. Despite full prescribing information on pill splitting in printed hospital formularies, inappropriate pill splitting is still not rare in clinical practice, which threatens patient safety.

Medication errors that lead to ADEs, which frequently occur during prescribing, are the most common cause of harm in outpatient settings and are often preventable [4, 5]. Recent studies suggest that a computerized clinical decision support system (CDSS) in computerized physician order entry (CPOE) system would be effective in preventing the prescribing errors [6–9]. However, little data is available regarding the impact of CDSS on the inappropriate pill splitting.

To reduce prescribing inappropriate pill splitting, in 2010, an automatic warning system at outpatient settings was developed in our hospital. In this study, we examined the impact of the warning system on the inappropriate prescribing of pill splitting in our ambulatory CPOE, and assessed the physicians’ responses to the warnings.

**Materials and Methods**

**Ethics Statement**

This study was approved by the institutional review board of Taipei Veterans General Hospital (2012-09-026B). Since the research posed no more than minimal
risk to the participants and involved no procedures, the review board agreed that written consent from patients was not required.

Setting
This study was conducted in an academic medical center which serves more than 2.5 million ambulatory visits per year in Taiwan. In average, about 8,000 prescriptions with 25,000 prescribed drug items were generated for ambulatory patients. All prescriptions were issued by physicians through CPOE that operated since 1993. This integrated CPOE system could perform dosage limit checks, drug duplication checks, drug-drug interaction checks, etc. Since June 2010, a specific interruptive warning system designed by a team of physicians, pharmacists and computer programmers, was integrated into CPOE for blocking prescriptions involving inappropriate pill splitting. We designed an intervention study to compare the inappropriate pill splitting before and after the implementation of the warning system. Baseline period was the 5 months before system implementation from January 1 to May 31 in 2010, and the intervention period was the 15 months after system implementation from June 1 in 2010 to August 31 in 2011.

Drugs with Special Oral Formulations
Drugs were recognized as “special oral formulations” if they were ER or EC formulations that were not originally intended to be split. The instruction leaflets accompanying the medicines documented drug formulation and indivisibility. Inappropriate prescribed drug items of pill splitting were defined as the drugs with special oral formulations were fragmented.

Prescribing Warnings
When prescribers submitted a non-integer quantity drug with special oral formulation, a real-time warning would pop up on the CPOE screen. The content of the pop-up warning included the drug’s name and a short warning message: “Drug should not be split. Please revise the prescription.” Prescribers had to adjust the drug regimen or change to another medication in response to these warnings in order to complete the prescription process. No further information would be provided after these warnings, such as alternatives or other educational information. However, prescribers could find drug information and lists of alternatives from other online resources.

Data Collection
Every prescription with special oral formulation drugs during the study period was logged from our ambulatory CPOE system. The measure of analysis was individual prescribed drug item. During intervention period, all prescribed drug items with warnings were collected and regarded as inappropriate drug items of
pill splitting. In the baseline period, inappropriate drug items of pill splitting were retrieved retrospectively by applying the same algorithm of the real warning system adopted in intervention period.

The warning rates of inappropriate splitting were calculated monthly. To minimize the effect of monthly order volume fluctuations and medical staff turnover, each 5-month period was defined as below for further statistical analysis: baseline period (5 months before intervention, from January 1 to May 31 in 2010); period 1 (the 1st–5th months after intervention, from June 1 to October 31 in 2010), period 2 (the 6th–10th months after intervention, from November 1 in 2010 to March 31 in 2011); and period 3 (the 11th–15th months after intervention, from April 1 to August 31 in 2011). We assumed that the warning rate would be stable after 1 year of system implementation, thus we performed the data up to the 15th month (period 3).

Any individual changes of prescriptions in respond to the warnings were confirmed by comparing interrupted prescriptions logged, final prescriptions, and medication history in our CPOE. At the time points of the first, second, twelfth and fifteenth months after intervention were analyzed.

Data Analysis

All data were linked by the SQL server 2008 (Microsoft Corp., Redmond, WA) and analyzed using the SAS software 9.1 (SAS Institute, Cary, NC, USA). Descriptive statistics was used to summarize prescribed drug items characteristics. The warning rates of prescribed drug items with inappropriate splitting before and after this warning system were compared using Poisson regression. Results were considered statistically significant at P<0.05.

Results

Thirty-four different drugs with special oral formulations in this study were shown in Support Information (Table S1). A total of 116,088 drug items with special oral formulations were prescribed during the 5-month baseline period, while 354,523 drug items with special oral formulations were prescribed during the 15-month intervention period. The detailed information on all inappropriate prescribed items involving special oral formulation drugs was shown in Table 1. During the intervention period, 909 prescribed drug items with warnings for 26 different drugs were detected, and 93.9% (854/909) were prescribed for adults. Of these drug items which triggered warnings, 24.6% (224/909) were prescribed by cardiologists, 13.8% (125/909) by psychiatrists and 11.9% (108/909) by endocrinologists. Central nervous system agents (45.7%, 415/909) and cardiovascular agents (38.6%, 351/909) showed the most frequent warnings. The top three drugs which most frequently triggered warnings were alprazolam ER tab 0.5 mg (22.2%, 202/909), fluvastatin ER tab 80 mg (18.8%, 171/909) and paliperidone ER tab 3 mg (6.9%, 63/909).
The inappropriate drug items associated with a warning had a rapid and sustained decrease after the implementation of the system (Figure 1). In the baseline period, the warning rate of inappropriate drug items was 0.61% (703/
116,088), and then the rate dropped to 0.41% (488/117,907) in period 1, 0.19% (235/121,979) in period 2, and 0.16% (186/114,637) in period 3. Compared with the baseline period, the incidence rate ratio (IRR) of warning rate was gradually reduced from period 1 (IRR 0.68, 95% CI 0.61–0.77, P<0.001), period 2 (IRR 0.32, 95% CI 0.27–0.37, P<0.001) to period 3 (IRR 0.27, 95% CI 0.23–0.31, P<0.001). The warning rate of inappropriate prescribing in period 2 decreased significantly (IRR 0.47, 95% CI 0.40–0.54, P<0.001), compared to period 1. However, there was no significant decrease from period 2 to period 3 (IRR 0.84, 95% CI 0.69–1.02, P=0.08).

When compared to the baseline period, the warning rate of inappropriate pill splitting at period 3 showed a significant reduction in prescribed drug items for adult patients (Table 2). The warning rate also significantly reduced by the end of the study period in the top 7 specialties (including cardiologists, endocrinologists, psychiatrists, neurologists, general internists, nephrologists, and surgeons) which showed the highest prescribing rate of inappropriate pill splitting in the baseline period. The warning rates of top 10 drugs with the most frequent warnings in the baseline period were also reduced, except for valproate EC tab 200 mg.

A total of 55 drug items with 13 different drugs were prescribed inappropriately for pediatric patients during 15-month intervention period. We found that serratiopeptidase tab 5 mg had a large percentage (50.9%, 28/55) of inappropriate drug items in pediatrics. Loratadine/pseudoephedrine repetabs tab 10/240 mg,
valproate EC tab 200 mg, potassium chloride tab 600 mg, and diphenylmethane EC tab 5 mg were observed in 12.7% (n=7), 9.1% (n=5), 5.5% (n=3) and 5.5% (n=3) of inappropriate items, respectively. As Table 2 showed, we found that the warning rates did not change in prescriptions for pediatrics. Among these 13 different drugs with special oral formulations, 5 different drugs had alternatives with liquid formulation. Another 7 different drugs had immediate-release formulation with same ingredient or efficacy. There was no suitable alternative drug for serratiopeptidase tab.

Four kinds of physicians’ responses to the warnings included changing to an unsplit pill by changing dose or frequency (72.9%, 248/340), switching to same-

Table 2. Comparison of warning prescriptions with inappropriate pill splitting in the baseline period and in the third intervention period, stratified by patient age, prescriber specialty and the specific drug.

| Drugs                          | Baseline Period | The 3rd Intervention Period | Incidence Rate Ratio | 95% CI        | P value |
|-------------------------------|-----------------|-----------------------------|----------------------|---------------|---------|
|                               | Baseline Period | The 3rd Intervention Period |                      |               |         |
|                               | 5 months        | 11th–15th month             |                      |               |         |
| Patient age                    |                 |                             |                      |               |         |
| ≤18 yrs                       | 14              | 2133 (0.66) 42 | 19206 (0.22) | 0.25          | 0.18–0.36 <0.001 |
| 18–64 yrs                     | 238             | 43960 (0.54) 75 | 7677 (0.35) | 0.22          | 0.14–0.33 <0.001 |
| ≥65 yrs                       | 451             | 69995 (0.64) 98 | 65523 (0.15) | 0.23          | 0.19–0.29 <0.001 |
| Prescriber specialty          |                 |                             |                      |               |         |
| Cardiology                    | 188             | 21906 (0.86) 42 | 19206 (0.22) | 0.25          | 0.18–0.36 <0.001 |
| Metabolism & endocrinology    | 137             | 8409 (1.63) 27 | 7677 (0.35) | 0.22          | 0.14–0.33 <0.001 |
| Psychiatry                    | 87              | 6983 (1.25) 27 | 7568 (0.36) | 0.29          | 0.19–0.44 <0.001 |
| Neurology                     | 85              | 10114 (0.84) 13 | 9801 (0.13) | 0.16          | 0.09–0.28 <0.001 |
| General medicine              | 47              | 6192 (0.76) 7 | 5110 (0.14) | 0.18          | 0.08–0.40 <0.001 |
| Nephrology                    | 45              | 5778 (0.78) 5 | 5889 (0.08) | 0.11          | 0.04–0.27 <0.001 |
| Surgery                       | 41              | 8305 (0.49) 17 | 17449 (0.10) | 0.20          | 0.11–0.35 <0.001 |
| Others                        | 73              | 48401 (0.15) 48 | 41937 (0.11) | 0.76          | 0.53–1.09 0.14 |

n, number of prescriptions with warnings; N, number of prescriptions with special oral formulations; %, n/N, proportion of prescriptions with warnings.

* Inappropriate prescriptions of pill splitting were retrieved retrospectively by applying the same algorithm of the real warning system adopted in intervention period.

doi:10.1371/journal.pone.0114359.t002
ingredient with different formulation or with the same formulation but lower strength (11.8%, 40/340), switching to different ingredient alternatives (10.3%, 35/340), and cancelling the drug item which triggered the warning (5.0%, 17/340). The physicians’ responses of the top 10 most frequently inappropriate prescribed drugs were also analyzed (Table 3). The proportion of waving prescription (50%, 4/8) in serratiopeptidase tab was highest.

### Discussion

The interruptive warning system showed clinical significant impact to avoid inappropriate pill splitting. After the system was implemented, the warning rate rapidly declined. In respond to warnings, physicians had to make adjustments. The warnings substantially affected the prescribing behavior in regard to pill splitting of special oral formulations.

The impact of an alert of inappropriate pill splitting in a CDSS has been reported. Quinzler et al. developed and implemented a CDSS which provided alerts of inappropriate pill splitting during the prescribing process for ambulatory patients or patients at discharge [10]. Their results showed that the CDSS application could significantly reduce the rate of inappropriate splitting. However, our study design differed from theirs. Our studied drugs were special oral formulations that did not allow splitting, while in the study of Quinzler et al., they included all capsules and unscored tablets which were unsuitable to be split.

### Table 3. Physicians’ responses of the top 10 frequent inappropriate drug prescriptions when receiving hard-stop warnings.

|                          | Total | Change to unsplit pill<sup>b</sup> | Switch to same ingredient product<sup>c</sup> | Switch to another ingredient product<sup>d</sup> | Waive prescription |
|--------------------------|-------|-----------------------------------|-------------------------------------------|-----------------------------------------------|-------------------|
| Total                    | 340   | 248 (72.9%)                       | 40 (11.8%)                                | 35 (10.3%)                                    | 17 (5.0%)         |
| Alprazolam XR tab 0.5 mg (Xanax) | 87    | 50 (57.5%)                        | 24 (27.6%)                                | 11 (12.6%)                                    | 2 (2.3%)          |
| Fluvastatin XL tab 80 mg (Lescol) | 80    | 67 (83.8%)                        | -<sup>e</sup>                             | 12 (15.0%)                                    | 1 (1.3%)          |
| Paliperidone ER tab 3 mg (Invega) | 7     | 6 (85.7%)                         | -<sup>e</sup>                             | 1 (14.3%)                                     | 0                 |
| Metformin ER tab 500 mg (Ansures) | 26    | 15 (57.7%)                        | 7 (26.9%)                                | 1 (3.8%)                                      | 3 (11.5%)         |
| Felodipine ER 5 mg (Plendil) | 19    | 8 (42.1%)                         | 6 (31.6%)                                | 3 (15.8%)                                     | 2 (10.5%)         |
| Bupropion SR tab 150 mg (Wellbutrin) | 24    | 20 (83.3%)                        | -<sup>e</sup>                             | 4 (16.7%)                                     | 0                 |
| Valproate EC tab 200 mg (Depakine) | 13    | 11 (84.6%)                        | 2 (15.4%)                                | 0                                             | 0                 |
| Doxazosin XL tab 4 mg (Doxaben) | 16    | 8 (50.0%)                         | 5 (31.3%)                                | 2 (12.5%)                                     | 1 (6.3%)          |
| Serratiopeptidase tab 5 mg (Danzen) | 8     | 4 (50.0%)                         | -<sup>e</sup>                             | -<sup>e</sup>                                 | 4 (50.0%)         |
| Diclofenac SR tab 75 mg (Meitifen) | 3     | 3 (100.0%)                        | 0 (0.0%)                                 | 0                                             | 0                 |
| Others                   | 57    | 50 (87.7%)                        | 2 (3.5%)                                 | 1 (1.8%)                                      | 4 (7.0%)          |

<sup>a</sup>At the points of the first (June, 2010), second (July, 2010), twelfth (May, 2011) and fifteenth (August, 2011) months after intervention.

<sup>b</sup>For example, 0.5 tab twice daily changed to 1 tab once daily; 0.5 tab once daily changed to 1 tab once daily; or 1.5 tab once daily changed to 1 tab once daily.

<sup>c</sup>Products with different formulations or with the same formulation but lower strength.

<sup>d</sup>Products with the same therapeutic effects.

<sup>e</sup>No available products in the study hospital.

DOI:10.1371/journal.pone.0114359.t003
whether they were ER/EC formulations or not. Based on pharmacokinetics, inappropriate splitting of extended-release or enteric-coated pills would affect drug efficacy and result in side effects. Therefore, splitting pills with special oral formulations should be forbidden. Recent studies also reported the adverse clinical consequence of tablet crushing [11, 12]. As for the normal capsules and tablets, split pills did not seem to affect the clinical outcomes in patients with hypertension, hyperlipidemia or psychiatric disorders [13]. This was the reason that we designed the warning system only for extended-release or enteric coated pills which did not allow splitting. In addition, our interruptive warning system can completely avoid the inappropriate splitting. Compared to the alert system in the study of Quinzler et al., only nearly half (2.7% decreased to 1.4%) of inappropriate splitting was prevented, which meant that still one half of alerts were overridden by prescribers.

In our study, a clear learning effect was observed on physicians’ practice behavior after the implementation of the warning system for prescriptions. After physicians experienced inappropriate splitting warnings, the warning rates showed a remarkable reduction. Inadequate physician knowledge about drug formulations may contribute to the majority of prescribing errors [14, 15]. Most clinicians have not continually received proper pharmacokinetic education regarding the use of drugs with special oral formulations, thereby resulting in prescription errors. We identified this limitation in physician education, so we implemented this warning system to avoid inappropriate pill splitting. Accordingly, prescribers changed their behavior on prescribing drugs with special oral formulations when they received a warning. The remained few warnings in the late intervention period might be due to (1) physicians who had never experienced the warning of a specific drug, or (2) physicians who forgot or neglected the indivisibility of special oral formulations.

We observed that the warning rate of inappropriate pill splitting in pediatric patients seemed not to be affected over the study period. A pediatric dosage must be adjusted by age, body weight and disease conditions. Thus, a lack of child-friendly formulations may result in pill splitting [16]. Even though some pills had alternatives with liquid formulations, physicians still preferred split pills. The reasons might be that liquids were more expensive or had unacceptable tastes [17]. It implied that more child-friendly formulations such as granules or chewable tablets may be introduced by the hospital to meet clinical needs.

In the analysis of the modifications in response to warnings, it was noteworthy that physicians cancelled certain prescriptions instead of shifting to alternatives. One of the possible reasons might be that the warnings forced physicians to reevaluate the necessity of drug use. In this study, serratiopeptidase was the only one with special oral formulations that had no alternative drug among 34 different drugs. When physicians received warnings of split serratiopeptidase, they had to change to unsplit pill or cancel the prescription. Serratiopeptidase is a proteolytic enzyme that had been used for relieving inflammation- and edema-associated conditions such as respiratory congestion, trauma, and infection [18]. However, the recommended dose of serratiopeptidase remains unclear particular to pediatrics [19]. In addition, serratiopeptidase is made as an enteric-coated tablet
to avoid inactivation of the enzyme activity by gastric acid. Splitting this tablet damaged the protective coating, which resulted in loss of efficacy. Furthermore, because the existing evidence of clinical efficacy of serratiopeptidase was insufficient [19], the renewal of drug license had been withdrawn by Taiwan Food and Drug Administration in 2011 [20]. Due to limited clinical benefit for patients, it seems rational that physicians gave up prescribing serratiopeptidase.

Although the CPOE with CDSS can reduce prescribing errors [21]; but new type of error can be resulted. For example, Strom et al. showed that hard-stop warnings can delay clinically important treatment for inpatients in need of immediate drug therapy [22]. However, our hard-stop warning system was set up in outpatient care, where fewer patients need urgent drug therapy. Furthermore, the possible unintended consequences of hard-stop warnings may occur which require further research.

Previous studies have indicated that inappropriate pill splitting could increase the risk of adverse events and even lead to treatment failure [2, 23]. The warning in prescribing process has been considered an important strategy to prevent medical harm [24]. Our results offer fundamental insights for warning of inappropriate pill splitting. However, the current study has some limitations. First, this study was carried out in a single hospital. The warning system was implemented in outpatient settings of a medical center where attending physicians prescribed the medications. Hence, the generalization of the results on other settings is unknown. Second, this non-randomization study had potential confounding variables, such as medical staff turnover. Third, because we intercepted all prescribed drug items of inappropriate pill splitting, adverse effects related to pill splitting would never occur. Thus we could not evaluate the true clinical impact of this warning system to patients. Fourth, we could not access the appropriateness of physicians' responses to the warnings because of limited data availability in this retrospective study.

Conclusions
Prescribing inappropriate pill splitting is not rare in clinical practice. The interruptive warning system avoided the prescriptions with inappropriate pill splitting. Physicians would change their behavior of prescribing drugs with special oral formulations owing to a hard-stop warning or a learning effect from previous warnings regarding inappropriate splitting. Thus, interruptive warning system should be developed and implemented in order to prevent prescribing inappropriate pill splitting.

Supporting Information
Table S1. Drugs with special oral formulations, selected from TVGH formulary.
doi:10.1371/journal.pone.0114359.s001 (DOCX)
Author Contributions
Conceived and designed the experiments: YCC C. Hsu Chia-Lin Chou Chia-Yu Chou C. Ho TJC. Performed the experiments: YCC C. Hsu Chia-Yu Chou MSW SCC. Analyzed the data: YCC C. Hsu Chia-Yu Chou Chia-Lin Chou TJC C. Ho. Wrote the paper: YCC C. Hsu Chia-Yu Chou Chia-Lin Chou. Designed the software: YCC C. Ho SWW CYL.

References

1. Arnold RJ, Kaniecki DJ (1993) Selection of oral controlled-release drugs: a critical decision for the physician. South Med J 86: 208–214.

2. Schier JG, Howland MA, Hoffman RS, Nelson LS (2003) Fatality from administration of labetalol and crushed extended-release nifedipine. Ann Pharmacother 37: 1420–1423.

3. Chou CY, Hsu CC, Chiang SC, Ho CC, Chou CL, et al. (2013) Association between Physician Specialty and Risk of Prescribing Inappropriate Pill Splitting. PLoS One 8: e70113.

4. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, et al. (1995) Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 274: 29–34.

5. Tache SV, Sonnichsen A, Ashcroft DM (2011) Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother 45: 977–989.

6. Saxena K, Lung BR, Becker JR (2011) Improving patient safety by modifying provider ordering behavior using alerts (CDSS) in CPOE system. AMIA Annu Symp Proc 2011: 1207–1216.

7. Seidling HM, Schmitt SP, Bruckner T, Kaltschmidt J, Pruszydlo MG, et al. (2010) Patient-specific electronic decision support reduces prescription of excessive doses. Qual Saf Health Care 19: e15.

8. Kadmon G, Bron-Harlev E, Nahum E, Schiller O, Haski G, et al. (2009) Computerized order entry with limited decision support to prevent prescription errors in a PICU. Pediatrics 124: 935–940.

9. Bobb A, Gleason K, Husch M, Feinglass J, Yarnold PR, et al. (2004) The epidemiology of prescribing errors: the potential impact of computerized prescriber order entry. Arch Intern Med 164: 785–792.

10. Quinzler R, Schmitt SP, Pritsch M, Kaltschmidt J, Haefeli WE (2009) Substantial reduction of inappropriate tablet splitting with computerised decision support: a prospective intervention study assessing potential benefit and harm. BMC Med Inform Decis Mak 9: 30.

11. Cornish P (2005) "Avoid the crush": hazards of medication administration in patients with dysphagia or a feeding tube. CMAJ 172: 871–872.

12. Emami S, Hamishehkar H, Mahmoodpoor A, Mashayekhi S, Asgharian P (2012) Errors of oral medication administration in a patient with enteral feeding tube. J Res Pharm Pract 1: 37–40.

13. Freeman MK, White W, Iranikah M (2012) Tablet splitting: a review of the clinical and economic outcomes and patient acceptance. Second of a 2-part series. Part 1 was published in May 2012 (Consult Pharm 2012; 27: 239–53),. Consult Pharm 27: 421–430.

14. Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, et al. (1995) Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA 274: 35–43.

15. Lesar TS, Briceland L, Stein DS (1997) Factors related to errors in medication prescribing. JAMA 277: 312–317.

16. Standing JF, Tuleu C (2005) Paediatric formulations—getting to the heart of the problem. Int J Pharm 300: 56–66.

17. Lajoinie A, Henin E, Kassai B, Terry D (2014) Solid oral forms availability in children - A cost-saving investigation. Br J Clin Pharmacol: (Article in press).

18. Mazzone A, Catalani M, Costanzo M, Drusian A, Mandoli A, et al. (1990) Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res 18: 379–388.
19. Bhagat S, Agarwal M, Roy V (2013) Serratiopeptidase: a systematic review of the existing evidence. Int J Surg 11: 209–217.

20. Ministry of Health and Welfare (8 March 2011) The renewal of drug license for serratiopeptidase had been withdrawn. Available: http://www.nhi.gov.tw/Resource/webdata/Attach_17637_2_100.3.8.pdf. Accessed 2014 October 8.

21. Ranji SR, Rennke S, Wachter RM (2014) Computerised provider order entry combined with clinical decision support systems to improve medication safety: a narrative review. BMJ Qual Saf 23: 773–780.

22. Strom BL, Schinnar R, Aberra F, Bilker W, Hennessy S, et al. (2010) Unintended Effects of a Computerized Physician Order Entry Nearly Hard-Stop Alert to Prevent a Drug Interaction A Randomized Controlled Trial. Archives of Internal Medicine 170: 1578–1583.

23. Lesar TS (2002) Prescribing errors involving medication dosage forms. J Gen Intern Med 17: 579–587.

24. Gillaizeau F, Chan E, Trinquart L, Colombet I, Walton RT, et al. (2013) Computerized advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev 11: CD002894.